SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Research collaboration

23 Mar 2016 07:00

RNS Number : 9617S
Collagen Solutions PLC
23 March 2016
Β 

23 March 2016

Collagen Solutions Plc

(the "Company" or the "Group")

Β 

Collaboration with The Blond McIndoe Research Foundation

Β 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces a research collaboration with Blond McIndoe Research Foundation ('BMRF'), a not for profit centre for regenerative medicine based at the Queen Victoria Hospital, East Grinstead, a world leading centre for the treatment of burns.

Β 

The pilot study will investigate the use of primary human skin cells used in formulation with Collagen Solutions products with a view to developing more effective treatments for burns, thereby reducing the burden and limitation of skin grafting. It is hoped that the combination of BMRF's experience in culturing cells specifically for treatment of burns and the use of high quality medical grade collagen will also enable the use of more effective application technologies for these types of injuries.

Β 

Dr Stewart White, Chief Executive Officer of Collagen Solutions said: "With over 13,000 UK hospital admissions* each year and 486,000** in the USA requiring medical attention, the care and treatment of burns presents a significant clinical need. We are extremely pleased to announce our collaboration with BMRF to work towards improved patient care. The experience the foundation has in the treatment of burns and wound care using the patient's own cells is truly world leading. Initially the project will confirm that our functional collagen formulations will provide a successful scaffold for these living cells. Based on successful outputs, we will then go on to jointly create a delivery process which can increase the ease of handling of these products by clinicians, alongside greater efficacy of the treatments themselves."

Β 

Maxine Smeaton, Chief Executive Officer of BMRF said: "We are delighted to announce this important partnership with Collagen Solutions. Working together we are utilising each other's experience and expertise in order to accelerate this vital work in cell delivery technologies. Collaborations of this nature are crucial to achieving high quality, impactful research that results in improved outcomes for people who have experienced serious, life-changing burn wounds."

Β 

*http://www.britishburnassociation.org/

**http://www.ameriburn.org/

Β 

Enquiries:

Collagen Solutions Plc

David Evans, Chairman

Tel: 07740 084 452

Stewart White, CEO

Tel: 0141 648 9100

Panmure Gordon & Co

Robert Naylor (Corporate Finance)

Maisie Atkinson (Corporate Broking)

Tel: 020 7886 2714Tel: 020 7886 2905

Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

Mike Wort

Mob: 07900 608 002

For Further information on the Blond McIndoe Research Foundation visit: www.blondmcindoe.org

Β 

Blond McIndoe Research Foundation

Β 

Maxine Smeaton, CEO

Tel: 01342 414 295

Β 

Mob: 07866 807720

Β 

Background to BMRF:

The Blond McIndoe Research Foundation (BMRF) is a not-for-profit centre for regenerative medicine. Our research supports people who have experienced life-changing damage or disfigurement as a result of serious burns, major soft tissue trauma or disease. Our programmes are focused on advancing wound healing techniques and technologies that aim to repair, restore and regenerate tissue and reduce debilitating scarring in order to improve function, form and comfort. Our co-location and strategic alliance with Clinicians at The Queen Victoria Hospital (QVH) in East Grinstead underpins our collective aspiration to deliver patient oriented innovations.Β 

Β 

We were founded in the name of surgical pioneer Sir Archibald McIndoe who treated many injured airmen during WW2, known as The Guinea Pig Club, and foresaw the need to advance the science of healing in order to benefit future generations. The pioneering spirit continued over the years leading to many significant developments such as ground breaking discoveries in graft rejection research which paved the way for the first microsurgical techniques such as toe to hand transplant. Some of our more recent innovations have included the development of sprayed skin cells for children's burns and new biomaterials designed to reconstruct tissue damaged by high energy trauma, such as blast injuries.

Β 

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
NRAPGUGUWUPQGRP
Date   Source Headline
29th Apr 20208:28 amRNSForm 8.5 (EPT/NON-RI)
28th Apr 20204:25 pmRNSForm 8.3 - Collagen Solutions plc
27th Apr 20204:22 pmRNSForm 8 (OPD) - Collagen Solutions plc
27th Apr 20202:58 pmRNSForm 8.3 - Collagen Solutions plc
27th Apr 202011:05 amRNSForm 8.3 - Collagen Solutions plc
24th Apr 20202:51 pmRNSForm 8.3 - Collagen Solutions Plc
24th Apr 20202:45 pmRNSForm 8.3
24th Apr 202012:21 pmRNSForm 8.3 - Collagen Solutions Plc
24th Apr 20209:40 amRNSForm 8.5 (EPT/NON-RI)
24th Apr 20207:00 amRNSDirector/PDMR Shareholding
23rd Apr 202012:10 pmGNWForm 8.3 - Collagen Solutions Plc
23rd Apr 20207:00 amRNSTrading update
22nd Apr 20201:30 pmRNSForm 8.3 - Collagen Solutions plc
22nd Apr 20209:27 amRNSForm 8.5 (EPT/NON-RI)
21st Apr 20209:31 amRNSForm 8.5 (EPT/NON-RI)
20th Apr 20208:21 amRNSForm 8.5 (EPT/NON-RI)
17th Apr 20202:33 pmRNSForm 8.3 - Collagen Solutions plc
17th Apr 202012:35 pmRNSForm 8.3 - Collagen Solutions plc
17th Apr 20208:35 amRNSForm 8.5 (EPT/NON-RI)
16th Apr 20207:00 amRNSStrategic Review and Formal Sale Process
18th Mar 20207:00 amRNSTrading update
3rd Dec 20197:00 amRNSHalf-year Report
19th Nov 20197:00 amRNSInvestor results presentation
13th Nov 20197:00 amRNSDirectorate Change
22nd Oct 20197:00 amRNSTrading Update & Notice of Results
3rd Oct 20197:00 amRNSDirector/PDMR Shareholding
29th Aug 20197:00 amRNSInvestor presentation
28th Aug 201911:29 amRNSResult of AGM
28th Aug 20197:00 amRNSAGM Statement
8th Aug 201910:53 amRNSDirector/PDMR Shareholding
24th Jul 20197:00 amRNSPosting of Annual Report and Notice of AGM
11th Jul 20197:00 amRNSDirector/PDMR Shareholding
9th Jul 201912:18 pmRNSHolding(s) in Company
9th Jul 20197:00 amRNSFinal Results
9th Jul 20197:00 amRNSDirectorate Change
13th Jun 20192:22 pmRNSNotice of Results
10th Jun 20195:13 pmRNSHolding(s) in Company
10th Jun 20195:09 pmRNSHolding(s) in Company
7th Jun 20199:38 amRNSHolding(s) in Company
6th Jun 20192:27 pmRNSHolding(s) in Company
6th Jun 201912:35 pmRNSHolding(s) in Company
6th Jun 20199:52 amRNSDirector/PDMR Shareholding
6th Jun 20197:00 amRNSAppointment of Non-Executive Director
5th Jun 201911:50 amRNSResult of General Meeting and Open Offer
23rd May 20197:00 amRNSInvestor presentation
20th May 20197:00 amRNSStrategic Investment, Placing and Open Offer
9th Apr 20198:08 amEQSCollagen Solutions's losses narrow on improved top line performance
9th Apr 20197:00 amRNSTrading Update
21st Mar 201911:36 amRNSHolding(s) in Company
21st Feb 20192:49 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.